315 related articles for article (PubMed ID: 20297862)
1. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System.
Poluzzi E; Raschi E; Motola D; Moretti U; De Ponti F
Drug Saf; 2010 Apr; 33(4):303-14. PubMed ID: 20297862
[TBL] [Abstract][Full Text] [Related]
2. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).
Poluzzi E; Raschi E; Moretti U; De Ponti F
Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):512-8. PubMed ID: 19358226
[TBL] [Abstract][Full Text] [Related]
3. Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System.
Teng C; Walter EA; Gaspar DKS; Obodozie-Ofoegbu OO; Frei CR
Int J Med Sci; 2019; 16(7):1018-1022. PubMed ID: 31341415
[No Abstract] [Full Text] [Related]
4. Torsades de pointes associated with fluoroquinolones.
Owens RC; Ambrose PG
Pharmacotherapy; 2002 May; 22(5):663-8; discussion 668-72. PubMed ID: 12013370
[TBL] [Abstract][Full Text] [Related]
5. Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system.
Ali Z; Ismail M; Khan F; Sajid H
Expert Opin Drug Saf; 2021 Jan; 20(1):101-107. PubMed ID: 33141610
[No Abstract] [Full Text] [Related]
6. Summary of Torsades de Pointes (TdP) Reports Associated with Intravenous Drug Formulations Containing the Preservative Chlorobutanol.
Woosley RD; Romero K; Heise CW; Gallo T; Tate J; Woosley RL
Drug Saf; 2019 Jul; 42(7):907-913. PubMed ID: 30888625
[TBL] [Abstract][Full Text] [Related]
7. The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project.
Raschi E; Poluzzi E; Salvo F; Koci A; Suling M; Antoniazzi S; Perina L; Hazell L; Moretti U; Sturkenboom M; Garbe E; Pariente A; De Ponti F
Drug Saf; 2016 Jan; 39(1):59-68. PubMed ID: 26446144
[TBL] [Abstract][Full Text] [Related]
8. QT prolongation with antimicrobial agents: understanding the significance.
Owens RC
Drugs; 2004; 64(10):1091-124. PubMed ID: 15139788
[TBL] [Abstract][Full Text] [Related]
9. Disproportionality analysis of buprenorphine transdermal system and cardiac arrhythmia using FDA and WHO postmarketing reporting system data.
Sessler NE; Walker E; Chickballapur H; Kacholakalayil J; Coplan PM
Postgrad Med; 2017 Jan; 129(1):62-68. PubMed ID: 27977317
[TBL] [Abstract][Full Text] [Related]
10. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.
Pearson EC; Woosley RL
Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):747-53. PubMed ID: 15918160
[TBL] [Abstract][Full Text] [Related]
11. How safe are recently FDA-approved antimicrobials? A review of the FDA adverse event reporting system database.
Khadem TM; van Manen RP; Brown J
Pharmacotherapy; 2014 Dec; 34(12):1324-9. PubMed ID: 25421400
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial-associated QT interval prolongation: pointes of interest.
Owens RC; Nolin TD
Clin Infect Dis; 2006 Dec; 43(12):1603-11. PubMed ID: 17109296
[TBL] [Abstract][Full Text] [Related]
13. Potential for linezolid-related blindness: a review of spontaneous adverse event reports.
Brown J; Aitken SL; van Manen RP
Pharmacotherapy; 2011 Jun; 31(6):585-90. PubMed ID: 21923442
[TBL] [Abstract][Full Text] [Related]
14. Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe.
Raschi E; Poluzzi E; Godman B; Koci A; Moretti U; Kalaba M; Bennie M; Barbui C; Wettermark B; Sturkenboom M; De Ponti F
PLoS One; 2013; 8(11):e81208. PubMed ID: 24278396
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database.
Li D; Chai S; Wang H; Dong J; Qin C; Du D; Wang Y; Du Q; Liu S
Front Pharmacol; 2023; 14():1259611. PubMed ID: 38186652
[No Abstract] [Full Text] [Related]
16. Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system.
Wu Z; Zhou P; He N; Zhai S
Front Cardiovasc Med; 2022; 9():966331. PubMed ID: 36352852
[TBL] [Abstract][Full Text] [Related]
17. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database.
Aström-Lilja C; Odeberg JM; Ekman E; Hägg S
Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):587-92. PubMed ID: 18449951
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of the risk factors for QT prolongation and associated drug-drug interactions in a cohort of medical inpatients.
Khan Q; Ismail M; Haider I; Ali Z
J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):109-115. PubMed ID: 29458991
[TBL] [Abstract][Full Text] [Related]
19. Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug.
Badshah A; Janjua M; Younas F; Halabi AR; Cotant JF
Am J Med Sci; 2009 Aug; 338(2):164-6. PubMed ID: 19680025
[TBL] [Abstract][Full Text] [Related]
20. Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient.
Gandhi PJ; Menezes PA; Vu HT; Rivera AL; Ramaswamy K
Am J Health Syst Pharm; 2003 Dec; 60(23):2479-83. PubMed ID: 14686224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
